Lv75
4350 积分 2023-01-10 加入
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
21小时前
待确认
Long-Term Safety of “4-Hour” Hemoadsorption Combined with Hemodialysis in Maintenance Hemodialysis Patients: A Multicenter Prospective Cohort Study
17天前
已完结
Efficacy of HA130 Hemoadsorption in Removing Advanced Glycation End Products in Maintenance Hemodialysis Patients
17天前
已完结
Hemoadsorption combined with hemodialysis versus hemodialysis alone on mortality in end-stage kidney disease: a randomized, open-label, multicenter trial
17天前
已关闭
Elevated serum levels of soluble adhesion molecules predict death in pre‐dialysis patients: association with malnutrition, inflammation, and cardiovascular disease
19天前
已完结
Claudin proteins as emerging therapeutic targets for solid tumours
21天前
已完结
Time to establish a consensus definition of clinical remission distinct from well-controlled asthma
1个月前
已关闭
Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer
1个月前
已完结
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
1个月前
已完结
T-cell regulation by CD28 and CTLA-4
2个月前
已完结
皖公网安备34019202002308
